| Literature DB >> 35453235 |
Marianne Moerer1, Roswitha Merle2, Wolfgang Bäumer1.
Abstract
To minimize the use of third- and fourth-generation cephalosporins and fluoroquinolones, the 2018 amendment to the regulations of veterinary pharmacies (TÄHAV) introduced legal restrictions in Germany. In an online survey among German veterinarians, we investigated the influence of these requirements on the use of antibiotics in the treatment of dogs and cats and the development of resistance rates. It was found that, on average, between 21% and 30% of daily treated dogs and cats received antimicrobial therapy. The TÄHAV amendment led to a less frequent use of highest priority critically important antimicrobials (HPCIA) in 79% (240/303) of respondents and less antimicrobial use in general in 36% (108/303). As a result of these legal changes, 63% (190/303) of participants requested antimicrobial susceptibility testing (AST) more frequently. Participants consulted ASTs particularly frequently for treatment of otitis externa with 63% (190/303), cystitis with 55% (168/303), wounds with 44% (132/303), and pyoderma with 29% (88/303). Veterinarians also noted an increased loss of antimicrobial efficacy, especially when treating these diseases. The results of our survey confirm that the TÄHAV amendment is having a positive impact on prudent antibiotic use, with participants performing more ASTs, using HPCIA less frequently, and choosing alternative antimicrobials for therapy.Entities:
Keywords: AST; HPCIA; antibiotic; companion animals; survey
Year: 2022 PMID: 35453235 PMCID: PMC9028039 DOI: 10.3390/antibiotics11040484
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Antibiotic use. Number of participating veterinarians estimating how many dogs and cats treated daily (%) received antibiotic treatment. Bars indicate the percentages reported. On average, between 21% and 30% of cats and dogs treated daily received antimicrobial therapy. A total of 303 questionnaires were analyzed.
Number, percentages, and 95% CI of responses to general antibiotic use as well as the impact of the TÄHAV amendment 2018 on the use of antimicrobials and AST. A total of 303 questionnaires of a survey among German veterinarians were analyzed.
| Absolute Number | Percentages | 95% CI | |
|---|---|---|---|
| Do you use topical or systemic antibiotics more frequently? | |||
| Topical more frequent | 19 | 6.3% | 4.05–9.59% |
| Systemic more frequent | 186 | 61.4% | 55.79–66.69% |
| About equally often | 98 | 32.3% | 27.33–37.8% |
| Are penicillins the antibiotics you use most often? | |||
| I agree | 283 | 93.3% | 90.03–95.69% |
| I partly agree | 12 | 4% | 2.28–6.79% |
| I disagree | 8 | 2.7% | 1.34–5.12% |
| Are HPCIA the antibiotics you rarely use? | |||
| I agree | 259 | 85.6% | 81.07–89% |
| I partly agree | 26 | 8.6% | 5.92–12.28% |
| I disagree | 18 | 5.8% | 3.79–9.19% |
| Do you use HPCIA less frequently since the 2018 amendment to the TÄHAV? | |||
| I agree | 240 | 79.2% | 74.29–83.4% |
| I partly agree | 31 | 10.2% | 7.3–14.16% |
| I disagree | 32 | 41.6% | 7.58–14.53% |
| Did the 2018 amendment to the TÄHAV lead to a general reduction in antimicrobial treatments? | |||
| I agree | 108 | 35.6% | 30.46–41.19% |
| I partly agree | 69 | 22.8% | 18.41–27.82% |
| I disagree | 126 | 41.6% | 36.17–47.21% |
| Have you had more AST done since the introduction of the TÄHAV amendment? | |||
| I agree | 190 | 62.7% | 57.13–67.96% |
| I partly agree | 60 | 19.8% | 15.71–24.66% |
| I disagree | 53 | 17.5% | 14–22% |
| Do you generally use penicillins as empirical treatment, due to the TÄHAV amendment? | |||
| I agree | 230 | 75.9% | 70.79–80.38% |
| I partly agree | 37 | 12.2% | 8.99–16.38% |
| I disagree | 36 | 11.9% | 8.71–16.01% |
| After AST, do penicillins more frequently need to be replaced by another substance, compared to other antimicrobial agents? | |||
| I agree | 73 | 24.1% | 19.62–29.21% |
| I partly agree | 103 | 34% | 28.89–39.5% |
| I disagree | 127 | 41.9% | 36.49–47.54% |
| Have you frequently used AST alongside with treatment or only when a change of antibiotic is needed? | |||
| Parallel with treatment | 135 | 44.7% | 39.2–50.34% |
| To change an antibiotic | 62 | 20.5% | 16.36–25.44% |
| Equally often parallel and to change the agent | 105 | 34.8% | 29.62–40.3% |
| For the treatment of which diseases do you need AST particularly often? | |||
| Otitis externa | 190 | 62.7% | 57.13–67.96% |
| Cystitis | 168 | 55.4% | 49.82–60.94% |
| Wounds | 132 | 43.6% | 38.1–49.19% |
| Pyoderma | 88 | 29% | 24.22–34.39% |
| Respiratory Infections | 71 | 23.4% | 19.01–28.52% |
| Diarrhea | 47 | 15.5% | 11.87–20.02% |
| From which species are samples most frequently sent in for resistance testing? | |||
| Cats | 19 | 6.3% | 4.05–9.59% |
| Dogs | 116 | 38.3% | 32.99–43.87% |
| Cats and Dogs equally often | 168 | 55.4% | 49.82–60.94% |
| What are owners’ reactions to additional costs due to antibiogram requirements? | |||
| They agree with submitting a sample. | 159 | 52.5% | 46.86–58.03% |
| They partly agree with submitting a sample. | 107 | 35.3% | 30.15–40.85% |
| They disagree with submitting a sample. | 37 | 12.2% | 8.99–16.38% |
Antibiotic use and AST. Number, percentages, and 95% CI of responses regarding the diseases of otitis externa, pyoderma, bite wounds, and cystitis according to the frequency of antibiotic use and AST. For this evaluation, 300 questionnaires for otitis externa, 292 for pyoderma, 290 for bite wounds, and 289 for cystitis were analyzed from a survey among German veterinarians.
| Cystitis | Otitis Externa | Pyoderma | Bite Wounds | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Absolute Number | Percentage | 95% CI | Absolute Number | Percentage | 95% CI | Absolute Number | Percentage | 95% CI | Absolute Number | Percentage | 95% CI | ||
| Antibiotic use | Always (80–100%) | 53 | 18.30% | 14.3–23.21% | 95 | 31.70% | 26.66–37.13% | 68 | 23.40% | 18.81–28.46% | 208 | 71.70% | 66.28–76.6% |
| Frequent (60–79%) | 95 | 32.90% | 27.71–38.48% | 111 | 37% | 31.73–42.6% | 89 | 30.60% | 25.48–35.98% | 59 | 20.30% | 16.11–25.35% | |
| Partly (40–59%) | 74 | 25.60% | 20.92–30.93% | 56 | 18.70% | 14.66–23.46% | 71 | 24.40% | 19.75–29.55% | 16 | 5.50% | 3.42–8.77% | |
| Rarely to never (0–39%) | 67 | 23.20% | 18.69–28.38% | 38 | 12.70% | 9.37–16.91% | 63 | 21.60% | 17.24–26.65% | 7 | 2.40% | 1.17–4.9% | |
| AST | Always (80–100%) | 36 | 12.50% | 9.14–16.76% | 18 | 6% | 3.83–9.28% | 18 | 6.20% | 3.93–9.53% | 13 | 4.50% | 2.64–7.52% |
| Frequent (60–79%) | 41 | 14.20% | 10.63–18.68% | 21 | 7% | 4.62–10.46% | 21 | 7.20% | 4.75–10.74% | 11 | 3.80% | 2.13–6.66% | |
| Partly (40–59%) | 66 | 22.80% | 18.37–28.01% | 42 | 14% | 10.53–18.38% | 30 | 10.30% | 7.29–14.29% | 28 | 9.70% | 6.76–13.6% | |
| Rarely (20–39%) | 105 | 36.30% | 31–42.02% | 147 | 49% | 43.39–54.63% | 150 | 51.40% | 45.66–57.05% | 95 | 32.80% | 27.61–38.36% | |
| Never (0–19%) | 41 | 14.20% | 10.63–18.68% | 72 | 24% | 19.52–29.14% | 73 | 25% | 20.38–30.27% | 143 | 49.30% | 43.6–55.04% | |
Cystitis. Number, percentages, and 95% CI of responses regarding the disease of cystitis according to the frequency of the used active ingredients and the antibiotic groups for which a loss of therapeutic success was observed. A total of 289 questionnaires from a survey among German veterinarians were analyzed for this evaluation.
| Absolute Number | Percentage | 95% CI | |
|---|---|---|---|
| Active ingredient | |||
| Penicillins | 216 | 74.7% | 69.43–79.4% |
| Fluoroquinolones | 51 | 17.6% | 13.68–22.46% |
| Trimethoprim-Sulfonamide | 18 | 6.2% | 3.98–9.63% |
| Others | 16 | 5.5% | 3.44–8.8% |
| Loss of antibiotic therapy success | |||
| No | 219 | 75.8% | 70.52–80.36% |
| Yes | 70 | 24.2% | 19.64–29.48% |
| Penicillins | 58/70 | 82.9% | 72.38–89.91% |
| Fluoroquinolones | 11/70 | 15.7% | 9.01–25.99% |
| Trimethoprim-Sulfonamide | 10/70 | 14.3% | 7.95–24.34% |
Otitis externa. Number, percentages, and 95% CI of responses regarding the disease of otitis externa according to the frequency of the used active ingredients and the antibiotic groups for which a loss of therapeutic success was observed. A total of 300 questionnaires from a survey among German veterinarians were analyzed for this evaluation.
| Absolute Number | Percentage | 95% CI | |
|---|---|---|---|
| Active ingredient | |||
| Polymyxin B | 135 | 45% | 39.47–50.66% |
| Gentamicin | 85 | 28.3% | 23.53–33.68% |
| Florfenicol | 63 | 21% | 16.77–25.96% |
| Others | 17 | 5.7% | 3.57–8.89% |
| Loss of antibiotic therapy success | |||
| No | 240 | 80% | 75.11–84.13% |
| Yes | 60 | 20% | 15.87–24.89% |
| Polymyxin B | 42/60 | 70% | 57.49–80.1% |
| Gentamicin | 14/60 | 23.3% | 14.44–35.44% |
| Marbofloxacin | 9/60 | 15% | 8.1–26.11% |
| Florfenicol | 4/60 | 6.7% | 2.62–15.93% |
Pyoderma. Number, percentages, and 95% CI of responses regarding the disease of pyoderma according to the frequency of the used active ingredients and the antibiotic groups for which a loss of therapeutic success was observed. A total of 292 questionnaires from a survey among German veterinarians were analyzed for this evaluation.
| Absolute Number | Percentage | 95% CI | |
|---|---|---|---|
| Active ingredient for superficial pyoderma | |||
| Fusidic acid | 103 | 35.4% | 30.02–40.91% |
| Polymyxin B | 64 | 22% | 17.55–27.01% |
| Neomycin | 56 | 19.2% | 15.07–24.08% |
| Active ingredient for deep pyoderma | |||
| Penicillins | 164 | 56.3% | 50.43–61.74% |
| Cephalosporins | 113 | 38.7% | 33.29–44.4% |
| Loss of antibiotic therapy success | |||
| No | 253 | 86.6% | 82.26–90.07% |
| Yes | 39 | 13.4% | 9.93–17.74% |
| Penicillins | 34/39 | 87.2% | 73.29–94.4% |
| Cephalosporins | 10/39 | 25.6% | 14.57–41.08% |
| Fluoroquinolones | 3/39 | 7.7% | 2.65–20.32% |
Bite wounds. Number, percentages, and 95% CI of responses regarding bite wounds according to the frequency of the used active ingredients and the antibiotic groups for which a loss of therapeutic success was observed. A total of 290 questionnaires from a survey among German veterinarians were analyzed for this evaluation.
| Absolute Number | Percentage | 95% CI | |
|---|---|---|---|
| Active ingredient | |||
| Penicillins | 274 | 94.5% | 91.23–96.58% |
| Others | 16 | 5.5% | 3.42–8.77% |
| Loss of antibiotic therapy success | |||
| No | 263 | 86.6% | 86.79–93.52% |
| Yes | 27 | 13.4% | 6.48–13.21% |
| Penicillins | 23/27 | 85.2% | 67.52–94.08% |
| Cefovecin | 6/27 | 22.2% | 10.61–40.76% |
| Fluoroquinolones | 4/27 | 14.8% | 5.92–32.48% |